1. Bristow MR, Hershberger RE, Port JD, et al. β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82(Suppl 1): 12–25.
2. Homey CJ, Vatner SF, Vatner DE. β-adrenergic receptor regulation in the heart in pathophysiologic states: abnormal adrenergic responsiveness in cardiac disease. Annu Rev Physiol. 1991;53:137–159.
3. Packer M. Pathophysiological mechanisms underlying the effects of β-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation. 1990;82(Suppl 1):77–88.
4. Ross EM, Gilman AG. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Goodman Gilman A, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basis of Therapeutics. New York: Macmillan; 1985:35–48.
5. Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In: Goodman Gilman A, Goodman LS, Rail TW, Murad F, eds. The Pharmacological Basic of Therapeutics. New York: Macmillan; 1985:145–180.